Inventories

3 Months Ended

Mar. 31, 2024

The principal categories of inventories were comprised of the following:


Inventory:	March 31, 2024		December 31, 2023

Raw materials and supplies	$	3,368	$	5,291
Work in process	1,359		2,037
Finished goods	7,201		3,052
Total	$	11,928	$	10,380

The Company capitalizes inventory costs associated with products when future commercialization is considered probable and the future economic benefit is expected to be realized, which is typically when regulatory approval is obtained for a drug candidate. As such, the Company began capitalizing costs related to inventory in May 2023 upon FDA approval of LUMRYZ. Manufacturing costs associated with inventory purchased or produced prior to FDA approval were recorded as research and development expense in prior periods.